Topic Listing for Inspire Pharmaceuticals

Abstracts Articles Acceleration Certain Stock-based Benefits
Accepted Agreed Access Proxy Materials Over Internet
Accrued Expenses Accumulated Other Comprehensive Loss
Administration Administrative Committee
Adopted Pursuant Advertising
Agreement Alan Holmer
Allergan Inc Allergan Inc Restasis Diquafosol
Allergan Inc-elestat Allergan Inc-restasis Prolacria
Amended Restated 1995 Stock Plan Amended Restated Director Compensation Policy
Amendment Amendment Restated Certificate Incorporation Increase Number Authorized Shares
Amendment Rights Agreement Amendment Standstill Agreement
Amendment Termination Amendment Termination Plan
Annual Cash Bonuses Appendix
Appointment Chairman Board Assignment Trademarks
Audit Committee Oversight Audit Committee Pre-approval Policies Procedures
Audit Committee Report Audit Fees
Audit Other Fees Audit-related Fees
Available Information Azasite
Azasite Phase Program Update Azasite Treatment Bacterial Conjunctivitis
Azasite Treatment Blepharitis Background
Base Salaries Base Salaries 2007
Base Salaries 2008 Basis Fair Value Estimate Share-based Payments
Basis Presentation Bears Costs Soliciting Proxies
Because Rely Trade Secrets Agreements Protect Some Intellectual Been Named Defendant Litigation Result Substantial Damages Costs
Beneficial Owner Shares Registered Name Broker Bank Beneficial Ownership Reporting Compliance
Benefits Benefits Perquisites
Bilastine Bilastine Polymorph Patent
Bilastine Seasonal Allergic Rhinitis Board Directors Recommending Approval Share Exchange
Board Rights Boehringer Ingelheim International Gmbh
Bonuses Canada
Cannot Sell Elestat Restasis Commercialize Product Candidates Governmental Cannot Sell Restasis Elestat Product Candidates Governmental Approvals
Capacity Capital Leases
Cardiovascular Research Development Cash Equivalents Interest Other Receivables
Cash Investments Balance Increased Recent 115 Equity Financing Caution Regarding Forward-looking Statements
Cautionary Statement Ceo Succession Plan
Ceo Succession Plan Announced Certain Corporate Transactions
Certain Portions Document Been Marked Indicate Confidential Information Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certifications
Change Control Change Control Agreements
Change Control Severance Agreements Change Control Severance Agreements Executive Benefit Plan
Change Control Severance Benefit Plan Change Vote After Submitting Proxy
Changes Base Salaries 2007 Changes Base Salaries 2008
Changes Base Salaries 2009 Changes Control Over Financial Reporting
Changes Disagreements Accountants Accounting Financial Disclosure Changes Specifications
Changing Vote Chief Executive Officer Compensation
Christy Shaffer Claims Procedures
Class Director Nominees Subject Election Annual Meeting Class Directors Not Subject Election Annual Meeting
Class Nominees Clinical Trials Take Longer Complete Cost Expect Adversely
Co-promotion Revenue 2006 Double 2005 Co-promotion Revenue Product Line
Co-promotion Revenues Based Part Allergans Revenue Recognition Policy Co-promotion Royalty Revenues Based Part Allergans Revenue Recognition
Code Business Ethics Code Conduct Business Ethics
Collaboration Agreements Collaborative Agreements Allergan Inc-elestat
Collaborative Research Development Collaborative Research Development Revenues
Commitments Contingencies Committee Authority
Committee Determinations Common Stock Price Been Highly Volatile Investment Decline
Common Stock Price Been Volatile Investment Decline Value Common Stock Warrants
Communicate Board Directors Comparison Cumulative Total Return
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Discussion Analysis
Compensation Philosophies Compensation Philosophy Objectives
Compensation Philosophy Overview Compensation Unrelated Severance Payments
Competition Complaints Product Recall
Complete Only Portion Funds Loan Advance Above Wired Complete Outgoing Wire Request Below Portion Funds Loan
Compliance Compliance Certificate
Comprehensive Loss Condensed Statements Operations
Conference Call Confidential
Confidential Information Confidentiality
Confidentiality Publication Public Announcements Consent Independent Registered Public Accounting Firm
Consequences Change Control Consequences Share Exchange Approved
Consequences Share Exchange Not Approved Consulting Agreement
Contingencies Continue Incur Operating Losses Period Longer Anticipated Amount
Continuing Directors Controls Procedures
Corporate Cost Sales
Credit Risk Critical Accounting Policies Estimates
Current Stock Market Credit Conditions Extremely Volatile Unpredictable Cystic Fibrosis
Cystic Fibrosis Foundation Therapeutics Inc Data Information Related Azasite
Dated 2006 Debt
Debt Commitments Contingencies Debt Other Commitments
Deductibility Compensation Deferred Compensation Stock Options
Deferred Compensation Stock Options Warrants Definitions
Delivery Denufosol
Denufosol Phase Development Program Denufosol Proceeding Phase Trials Cystic Fibrosis
Denufosol Tetrasodium Denufosol Tetrasodium Ins37217 Ophthalmic Treatment Retinal Disease
Denufosol Tetrasodium Ins37217 Respiratory Treatment Cystic Fibrosis Denufosol Tetrasodium Treatment Cystic Fibrosis
Departure Directors Principal Officers Election Appointment Depend Pharmaceutical Wholesalers Vast Majority Azasite Sales United
Depend Wholesalers Vast Majority Azasite Revenues United States Dependence Collaborative Relationships Lead Delays Product Development Lost
Designation Specific Supplier Partner Detailed Results Presented North American Cystic Fibrosis Conference
Development Development Plan
Development Status Did Receive Notice Mail Regarding Internet Availability Proxy
Diquafosol Treatment Dry Eye Director Compensation
Directors Executive Officers Corporate Governance Directors Executive Officers Registrant
Directors Nonqualified Stock Option Directors Nonqualified Stock Option Grant Agreement
Directors Officers Sign Lock-up Agreement Disclaimer
Discovery Discretionary Awards
Discussion Risks Associated Development Programs Please See Risk Documentation Reports
Documents Incorporated Reference Dry Eye
Dry Eye Disease Durasite
Durham 2007 Inspire Pharmaceuticals Inc Nasdaq Isph Announced Ecitals
Election Directors Elestat
Eligibility Eligibility Participation
Employee Benefit Plan Employees
Entering Material Definitive Agreement Entry Material Definitive Agreement
Epinastine Nasal Spray Epinastine Nasal Spray Allergic Rhinitis
Epinastine Nasal Spray Seasonal Allergic Rhinitis Equity Compensation
Equity Compensation Plan Equity Compensation Plan Information
Equity Compensation Plans Estimated Development Costs Difficult Project Change Frequently Prior
Estimates Evaluation Disclosure Controls Procedures
Even Trial 03-113 Successful Meeting Primary Endpoint Fda Exact Name Registrant Specified Charter
Except Per Share Amounts Executive Compensation
Executive Officer Change Control Agreements Executive Officers Not Directors
Executives Covenants Exercise Options
Exhibits Existing Principal Stockholders Hold Substantial Amount Common Stock
Faes Farma Fail Reach Milestones Make Annual Minimum Payments Otherwise
Failure Adequately Control Compliance Applicable Laws Regulations Adversely Failure Adequately Control Compliance Applicable Regulations Adversely Affect
Failure Adequately Ensure Compliance Applicable Laws Regulations Adversely Failure Adequately Ensure Compliance Applicable Laws Regulations Subject
Failure Adequately Market Commercialize Azasite Limit Revenues Failure Adequately Market Commercialize Azasite Negatively Impact Revenues
Failure Adequately Market Commercialize Azasite Prolacria Other Product Failure Adequately Market Commercialize Diquafosol Approved Fda Limit
Failure Adequately Market Commercialize Prolacria Approved Fda Limit Failure Adequately Market Commercialize Prolacria Limit Revenues
Failure Comply Applicable Regulations Including Those Require Obtain Failure Hire Retain Key Personnel Hinder Product Development
Failure Hire Retain Key Personnel Identify Appoint Elect Failure Successfully Market Co-promote Allergans Restasis Elestat Negatively
Failure Successfully Market Commercialize Restasis Elestat Limit Revenues Failure Successfully Market Commercialize Restasis Elestat Negatively Impact
Failure Timely Adequately Market Commercialize Azasite Limit Revenues Failure Timely Adequately Market Commercialize Other Product Candidates
Fair Value Measurements Fda Not Conclude Product Candidates Meet Statutory Requirements
Federal Income Tax Consequences Fees Expenses
Final Audited Study Reports Financial Covenant Loan Agreement Amended Restated Entirety Follows
Financial Guidance Financial Guidance 2005
Financial Outlook 2008 Financial Outlook 2009
Financial Statements Financial Statements Exhibits
Financial Statements Supplementary Data Find Information
Force Majeure Event Foreign Currency Exchange Risk
Form 10-q Form Lock-up Agreement
Former Name Address Changed Since Last Report Forward Looking Information
Forward Looking Statements Forward-looking Statements
Fractional Shares Full Revenue Increased Over 2006
Funding Plan Further Amendment Plan
Future Implementation Certain Government Initiatives Create Risks Business Future Sales Issuances Securities Dilute Ownership Interests Current
Future Sales Securities Cause Stock Price Decline Future Sales Securities Dilute Ownership Interests Current Stockholders
Future Sales Stockholders Public Market Cause Stock Price General
General Administrative Expenses General Provisions
General Release Glaucoma Product Candidates
Governmental Regulation Grant License
Granting Options Grants
Greement Gregory Mossinghoff
Had Limited Experience Commercialization Products Had Limited Experience Sales Marketing Distribution Products
Had Limited Experience Sales Marketing Products Headings
Health Care Reform Measures Party Reimbursement Health Care Reform Measures Third-party Reimbursement
Held 2005 Held 2006
Held 2007 Held 2008
Held 2009 Householding Proxy Materials
Immediate Release Impact Inflation
Impact Recently Issued Accounting Pronouncements Implementation Objectives
Incentive Stock Option Incentive Stock Option Grant Agreement
Incentive Stock Options Income Taxes
Indemnification Independence Directors
Independent Registered Public Accounting Firm Index
Index Financial Statements Information Regarding Plans Other Arrangements Not Subject Stockholder
Initial Payment Milestone Initial Payment Milestone Payments
Initiated Two-center Patient Pediatric Double-blind Randomized Placebo-controlled Initiation Azasite Blepharitis Phase Program 2009 Partially Offset
Ins115644 Glaucoma Ins117548 Treatment Glaucoma
Ins37217 Respiratory Denufosol Tetrasodium Treatment Cystic Fibrosis Ins50589 Antiplatelet
Ins50589 Antiplatelet Acute Cardiac Care Ins50589 Antiplatelet Treatment Cardiovascular Diseases
Insite Vision Incorporated Inspire
Inspire Adds Industry Expert Alan Holmer Board Directors Inspire Announces Appointment Chairman
Inspire Announces Development License Agreement Boehringer Ingelheim International Inspire Announces European Orphan Drug Designation Denufosol Tetrasodium
Inspire Announces Fda Approval Azasite Trade New Product Inspire Announces Financing Warburg Pincus
Inspire Announces Issuance Patent Elestat Inspire Announces Outcome Fda Meeting Dry Eye Program
Inspire Announces Passing Chairman Leigh Thompson Inspire Announces Plans Begin Phase Testing Intranasal Epinastine
Inspire Announces Positive Results Phase Trial Epinastine Nasal Inspire Announces Progress Cystic Fibrosis Program Results Pediatric
Inspire Announces Receipt Fda Approvable Letter Diquafosol Inspire Announces Receipt Milestone Payment Japanese Dry Eye
Inspire Announces Results Phase Dry Eye Study Inspire Announces Sec Investigation
Inspire Announces Termination Bilastine Licensing Agreement Inspire Begins Phase Clinical Program Epinastine Seasonal Allergic
Inspire Continues Discussions Fda Dry Eye Program Inspire Director William Ringo Resign Board Position
Inspire Elects Alan Holmer Board Directors Inspire Faes Farma Amend Bilastine Licensing Agreement
Inspire Initiates Phase Clinical Trial Denufosol Tetrasodium Cystic Inspire Initiates Phase Cystic Fibrosis Trial
Inspire Names Joseph Spagnardi Senior Vice President General Inspire Pharmaceuticals Inc
Inspire Pharmaceuticals Inc 2005 Equity Compensation Plan Inspire Pharmaceuticals Inc Borrower
Inspire Provides Cystic Fibrosis Clinical Program Update Inspire Provides Update Cystic Fibrosis Program
Inspire Reports 2005 Financial Results Insurance
Insurance Coverage Increasingly Costly Difficult Obtain Maintain Insurance Coverage Increasingly Difficult Obtain Maintain
Intangible Assets Intellectual Property
Intellectual Property Protection Inadequate Development Possible Sales Product Intellectual Property Rights
Interest Certain Persons Share Exchange Interest Rate Risk
Interest Rate Sensitivity Internal Control Over Financial Reporting
Internet Information Intranasal Epinastine
Introduction Inventories
Investigation Securities Exchange Material Adverse Effect Business Investment Risk
Investments Invoice Payment
Involvement Certain Legal Proceedings Irector Ompensation Olicy
Kirin Brewery Ltd Pharmaceutical Division Launched Azasite United States Promoting Eye Care
Launching Azasite 13th Legal Proceedings
Liabilities Liability Indemnification
License Agreement License Agreements
License Development Marketing Agreement Licensed Patents
Licenses Exclusivity Limitation Amendments
Limitations Liability Linical Ervices Greement
Liquidity Capital Resources Litigation
Loan Payment Advance Request Form Loan Security Agreement
Loss Commercial Exclusivity Elestat Material Impact Cash Flows Managements Report Internal Control Over Financial Reporting
Manufacture Denufosol Manufacture Supply Api
Manufacturing Concentration Receivables Risk Manufacturing Services Agreement
Manufacturing Supply Manuscripts Progress
Market Common Equity Related Stockholder Matters Issuer Purchase Market Common Equity Related Stockholder Matters Issuer Purchases
Materials Medicare Prescription Drug Coverage Legislation Future Legislative Regulatory
Meetings Committees Board Meetings Committees Board Directors
Method Severance Payments Minimum Commitment Purchase Orders Forecasts
Minimum Royalties Miscellaneous
Motion Dismiss Granted Nacfc Denufosol Presentation Details
Name Person Filing Proxy Statement Other Registrant Name Registrant Specified Charter
Nasdaq Marketplace Rule Stockholder Approval Need Develop Alternate Dosing Regimens Product Candidates
Net Income Loss Per Common Share Net Loss Per Common Share
New York 10017 Next Steps
Nonqualified Deferred Compensation Nonqualified Stock Option
Nonqualified Stock Option Grant Agreement Nonqualified Stock Options
Not Able Obtain Sufficient Additional Funding Meet Expanding Not Able Successfully Compete Other Biotechnology Companies Established
Not Receive Timely Regulatory Approvals Product Candidates Successfully Not Successful Efforts Expand Product Portfolio
Not Successfully Market Promote Elestat Revenues Negatively Impacted Notes Condensed Financial Statements
Notes Financial Statements Notice
Nspire Harmaceuticals 2005 Quity Ompensation Lan Obtain Paper Copy Proxy Materials
Off Balance Sheet Arrangements Open-label Extension Suggests Progressive Improvement Fev
Operating Leases Operations Involve Risk Injury Hazardous Materials Very Expensive
Ophthalmic Research Associates Ophthalmic Research Associates Inc
Ophthalmic Research Development Ophthalmology Research Development
Optimization Tiger-2 Trial Design Option Exercises Stock Vested
Option Exercises Stock Vested 2007 Option Exercises Stock Vested 2008
Option Grants 2004 Option Grants 2005
Option Terms Options
Ora Orders Forecasting Eighteen Supply Delivery
Organization Other Assets
Other Changes Base Salary 2008 Other Commitments
Other Equity Plans Other Events
Other Fees Other Income
Other Income Expense Other Information
Other Matters Outflow Enhancer
Outlook Provided Overview
Overview Compensation Directors Related Matters P2y Receptor Antagonist Inhibition Platelet Aggregation
Part Part Other Information
Participation Eligibility Benefits Passing Title Risk Loss Api
Patent Protection Inadequate Development Possible Sales Product Candidates Patents Proprietary Rights
Payment Milestones Pension Benefits
Persons Respond Collection Information Contained Form Not Required Physicians Patients Not Accept Product Candidates They Commercially
Platelet Aggregation Inhibitor Please Send Development Reports
Preamble Previous Non-employee Director Compensation Policy
Price Price Api
Pricing Payment Primary Accounts Loan Agreement Amended Restated Entirety Follows
Principal Accountant Fees Services Product Co-promotion
Product Co-promotion Revenues Product Co-promotion Royalty
Product Co-promotion Royalty Revenues Product Revenues
Product Sales Net Products
Products Result Product Liability Claims Not Adequate Insurance Profit Sharing Plan
Projected Development Costs Difficult Estimate Change Frequently Prior Prolacria Diquafosol Tetrasodium Ophthalmic Solution
Prolacria Diquafosol Tetrasodium Treatment Dry Eye Disease Prolacria Dry Eye
Prolacria Trial Dry Eye Properties
Property Equipment Propose Actions Consideration Next Annual Meeting Stockholders
Proxy Solicited Behalf Board Directors Pulmonary Research Development
Pursuant Sections Securities Exchange Act 1934 Qualified Performance-based Compensation
Quality Control Related Matters Quantitative Qualitative Disclosures Market Risk
Quarterly Financial Data Ratification Selection Independent Registered Public Accounting Firm
Reasons Stockholder Approval Receiving Materials
Recent Accomplishments 2004 Through 2005 Recent Accounting Pronouncements
Recent Medicare Prescription Drug Coverage Legislation Future Legislative Recent Updates Include 2006 Through
Recent Updates Include 2007 Through Recent Updates Include 2007 Through 2008
Recent Updates Include 2008 Through Recent Updates Include 2008 Through 2009
Recent Updates Include 2009 Through Recitals
Reclassifications Records Regulatory Matters
Registrants Telephone Number Including Area Code 919 941-9777 Registration Rights Agreement
Rejection Replacement Defective Api Relative Stock Performance
Reliance Single Party Manufacture Supply Either Finished Product Rely Parties Distribute Sell Products Those Not Perform
Rely Parties Market Distribute Sell Some Products Those Rely Substantially Parties Market Distribute Sell Products Those
Remainder Page Intentionally Left Blank Report Independent Registered Public Accounting Firm
Representations Warranties Representations Warranties Covenants
Required Vote Recommendation Board Directors Requirements Issuance Transfer Shares
Research Development Research Development Expenses
Research Preclinical Development Respiratory Allergy Research Development
Restasis Restasis Not Successfully Commercialized Allergan Revenues Negatively Impacted
Restasis Not Successfully Commercialized Revenues Negatively Impacted Restricted Deposits
Restricted Stock Restricted Stock Units
Restructuring Results Operations Financial Condition
Results Provides 2005 Financial Guidance Revenue
Revenue Increased Over 2007 Revenue Increased Over 2008
Revenue Increases 2005 Revenue Increases 2005-
Revenue Product Line Revenue Raises Guidance
Revenue Recognition Revenues
Revenues Future Periods Vary Significantly Not Cover Operating Revised Financial Outlook 2007
Rights Agreement Rights Participants
Risk Factors Risk Generic Competition
Risks Party Manufacturing Concentration Risks Party Manufacturing Distribution Concentration
Risks Related Manufacture Supply Risks Related Product Development
Risks Related Stock Role Executive Officers Compensation Decisions
Sale Exchangeable Preferred Stock Sales Common Stock
Sales Marketing Santen Pharmaceutical Ltd
Santen Pharmaceuticals Ltd Sarbanes-oxley Act 2002
Schedule Investors Seasonal Allergic Rhinitis
Sec Investigation Securities Exchange Act 1934
Securities Purchase Agreement Between Inspire Warburg Securities Registered Pursuant Act
Securities Registered Pursuant Act Title Class Security Ownership Certain Beneficial Owners Management Related Stockholder
Seeking Stockholder Approval Share Exchange Selected Balance Sheet Information
Selling Marketing Expenses Severance Payments
Share Exchange Structured Shares Common Stock
Shares Exchangeable Preferred Stock Not Exchanged Common Remain Shares Subject 2005 Plan
Shares Subject Amended Plan Shares Subject Plan
Signature Signature Page Follow
Signature Page Follows Signature Page Immediately Follows
Signatures Signatures Following Page
Significant Customers Risk Since Clinical Candidates Utilize New Different Mechanisms Action
Since Clinical Candidates Utilize New Mechanism Action Some Since Rely Trade Secrets Agreements Protect Some Intellectual
Since Some Clinical Candidates Utilize New Different Mechanisms Special Protocol Assessment Agreement
Specifications Standstill Agreement
Stock Appreciation Right Stock Appreciation Right Grant Agreement
Stock Appreciation Rights Stock Appreciation Rights Sars
Stock Award Stock Award Grant Agreement
Stock Awards Stock Option Expense
Stock Options Stock-based Compensation
Stock-based Compensation Expense Stockholder Communication Board Directors
Stockholder Proposals Stockholder Proposals 2008 Annual Meeting Stockholders
Stockholder Proposals Director Nominations Other Information Stockholder Record Shares Registered Name
Stockholders Entitled Vote Stockholders Equity
Strategic Investment Risk Strategy
Study Results Guidelines Subject Fraud Abuse Similar Government Laws Regulations Failure
Submission Matters Vote Security Holders Submitted Chapters Manuscripts
Subscription Rights Subsequent Events
Summary Compensation Table Summary Directors Nonqualified Stock Option
Summary Incentive Stock Option Grant Summary Nonqualified Option Grant
Summary Preferred Stock Financing Summary Stock Appreciation Right Grant
Summary Stock Award Grant Supplemental Disclosure Non-cash Investing Financing Activities Acquired Property
Supplemental Information Supply Agreement
Table Contents Tally Sheets
Tax Considerations Tax Fees
Tax Withholding Taxes
Technical Information Process Validation Pre-approval Inspection Telephone 919941977 Fax 9199419797
Telephone 9199419777 149 Fax 9199419797 Telephone 9199419777 Fax 9199419797
Term Termination Term Termination Remedies
Terminated Agreement-ophthalmic Research Associates Inc Termination
Termination Commitment Lend Loan Agreement Amended Restated Entirety Termination Procedures Compensation Dispute
Terms Terms Exchangeable Preferred Stock
Terms Financing Testing Samples Release
Third-party Vendor Manufacturing Denufosol Api Related Prolacria Santens Tiger-1
Tiger-1 Open-label Safety Extension Status Tiger-2 Enrollment Status
Title Class Trade Receivables
Trademark License Agreement Trademarks
Transfer Stock Options Transferability
Transferability Grants Transition Agreement
Treatment Corneal Wound Healing Treatment Dry Eye Disease
Treatment Macular Edema Treatment Retinal Detachment
Types Grants Available 2005 Plan Types Grants Available Amended Plan
Unable Contract Parties Synthesis Active Pharmaceutical Ingredients Required Unable Contract Parties Synthesis Apis Required Preclinical Testing
Unable Make Scheduled Principal Interest Payments Term Loan Underwriting Agreement
Unit Pricing Fees Minimum Requirement United States
University North Carolina Chapel Hill Unresolved Staff Comments
Validation Processing Related Services Value
Vote Vote Annual Meeting
Vote Special Meeting Votes
Votes Counted Votes Needed Approve Each Proposal
Warburg Able Exercise Substantial Control Over Business Warburg Pincus
Warburg Pincus Able Exercise Substantial Control Over Business Warburg Pincus Private Equity
Warburg Pincus Transaction What Board Directors Voting Recommendation
What Happens Share Exchange Approved What Happens Share Exchange Not Approved
What Included Proxy Materials What Mean Receive Proxy Card
What Proposals Voted Annual Meeting What Purpose Special Meeting
What Quorum Requirement What Receive Notice Internet Availability Proxy Materials Paper
What Return Proxy Card Not Make Specific Choices What Voting
Wire Transfer Instructions Wire Transfer Instructions Redemption Amount
Wisconsin Alumni Research Foundation Withholding Taxes
Witnesseth Year-end Stock Option Values
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki